Search Within

Population Sciences Research Program

  1. "Maria Palomba"
  2. "Paul Hamlin"
  3. "Ahmet Dogan"
  4. "Bone Marrow Transplant"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Bone Marrow Transplant (7)
  2. Center for Hematologic Malignancies (7)
  3. Department of Medicine (7)
  4. Hematologic Malignancies, Division of (7)
  5. Lymphoma (7)
  6. Survivorship Research (6)

More Groups

People
  1. Ahmet Dogan (7)
  2. Ariela Noy (7)
  3. Maria Palomba (7)
  4. Paul Hamlin (7)
  5. Alison Moskowitz (6)
  6. Andrew Zelenetz (6)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2017 (2)
  4. 2016 (1)
  5. 2015 (1)
  6. 2014 (1)
Publications
  1. Blood (5)
  2. Cancer Discovery (1)
  3. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (5)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma
    Journal Article

    Grommes, C.; Pastore, A.; Palaskas, N.; Tang, S. S.; Campos, C.; Schartz, D.; Codega, P.; Nichol, D.; Clark, O.; Hsieh, W. Y.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save